...
首页> 外文期刊>Journal of Clinical Microbiology >Genotyping Multidrug-Resistant Mycobacterium tuberculosis from Primary Sputum and Decontaminated Sediment with an Integrated Microfluidic Amplification Microarray Test
【24h】

Genotyping Multidrug-Resistant Mycobacterium tuberculosis from Primary Sputum and Decontaminated Sediment with an Integrated Microfluidic Amplification Microarray Test

机译:利用整合的微流扩增芯片试验对来自原发痰和去污沉积物的耐多药结核分枝杆菌结核分枝杆菌进行基因分型

获取原文
           

摘要

ABSTRACT There is a growing awareness that molecular diagnostics for detect-to-treat applications will soon need a highly multiplexed mutation detection and identification capability. In this study, we converted an open-amplicon microarray hybridization test for multidrug-resistant (MDR) Mycobacterium tuberculosis into an entirely closed-amplicon consumable (an amplification microarray) and evaluated its performance with matched sputum and sediment extracts. Reproducible genotyping (the limit of detection) was achieved with ~25 M. tuberculosis genomes (100 fg of M. tuberculosis DNA) per reaction; the estimated shelf life of the test was at least 18 months when it was stored at 4°C. The test detected M. tuberculosis in 99.1% of sputum extracts and 100% of sediment extracts and showed 100% concordance with the results of real-time PCR. The levels of concordance between M. tuberculosis and resistance-associated gene detection were 99.1% and 98.4% for sputum and sediment extracts, respectively. Genotyping results were 100% concordant between sputum and sediment extracts. Relative to the results of culture-based drug susceptibility testing, the test was 97.1% specific and 75.0% sensitive for the detection of rifampin resistance in both sputum and sediment extracts. The specificity for the detection of isoniazid (INH) resistance was 98.4% and 96.8% for sputum and sediment extracts, respectively, and the sensitivity for the detection of INH resistance was 63.6%. The amplification microarray reported the correct genotype for all discordant phenotype/genotype results. On the basis of these data, primary sputum may be considered a preferred specimen for the test. The amplification microarray design, shelf life, and analytical performance metrics are well aligned with consensus product profiles for next-generation drug-resistant M. tuberculosis diagnostics and represent a significant ease-of-use advantage over other hybridization-based tests for diagnosing MDR tuberculosis.
机译:摘要人们日益认识到,从检测到治疗的分子诊断将很快需要高度多重的突变检测和鉴定功能。在这项研究中,我们将耐多药(MDR)结核分枝杆菌的开放扩增子微阵列杂交测试转换为完全封闭的扩增子耗材(扩增微阵列),并通过匹配的痰液和沉淀物提取物评估了其性能。每个反应使用约25个结核分枝杆菌基因组基因(100 fg结核分枝杆菌DNA)即可实现可重复的基因分型(检测限);当将其保存在4°C下时,该测试的估计保存期限至少为18个月。该测试在99.1%的痰液提取物和100%的沉淀物提取物中检测到结核分枝杆菌,并与实时PCR结果显示100%的一致性。痰和沉积物提取物结核分枝杆菌与耐药相关基因检测的一致性水平分别为99.1%和98.4%。痰液和沉积物提取物的基因分型结果一致。相对于基于培养物的药敏测试结果,该测试对痰液和沉淀物提取物中的利福平耐药性检测具有97.1%的特异性和75.0%的敏感性。痰液和沉淀物提取物对异烟肼(INH)耐药性的检测特异性分别为98.4%和96.8%,而对INH耐药性的检测灵敏度为63.6%。扩增微阵列报告了所有不一致表型/基因型结果的正确基因型。根据这些数据,可以将原发痰视为该检查的首选标本。扩增微阵列设计,保质期和分析性能指标与下一代耐药性结核分枝杆菌诊断的共识产品概况完全吻合,并且相对于其他基于杂交的诊断MDR结核病的测试而言,具有明显的易用性优势。

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号